Procyon Diagnostics

What Procyon Diagnostics does

Procyon Diagnostics Limited is a UK-based (Skipton, England) spinout company, founded in 2025 from Queen Mary University of London, commercialising clinical biomarker technology for early cancer detection. Its sole product is PancRISK, a non-invasive pancreatic cancer detection test that uses a patented three-protein urinary panel analysed via standard ELISA methodology and processed through a proprietary risk-score algorithm (incorporating machine learning) to classify individuals as increased or average risk. The test is reported to detect early-stage (Stage I-II) pancreatic cancer with approximately 90% accuracy and to identify disease up to two years before clinical diagnosis.

The company is currently validating PancRISK in the UroPanc observational clinical trial (NCT04449406), funded by the Pancreatic Cancer Research Fund, with trial completion expected in September 2027. Intended end-users are individuals with hereditary risk factors and patients presenting with vague symptoms potentially associated with pancreatic cancer; intended downstream customers are healthcare providers and clinical laboratories in Europe, North America, and the Middle East. Two granted patents cover the biomarker panel and the PancRISK risk-score algorithm.

Commercially Procyon has not yet launched PancRISK (targeted for Q4 2026) and has not disclosed pricing. The stated revenue model is one-time licence / kit sales of diagnostic tests to clinical laboratories and hospitals using standard ELISA instrumentation, with revenue mechanics pending commercial rollout. The company is pre-revenue and in the pre-launch clinical-validation phase with a small disclosed leadership team spanning academic invention, IVD commercialisation, and corporate finance.

Name

Procyon Diagnostics

Legal name

Procyon Diagnostics Limited

Website

https://procyondx.com

Company type

Private

Founded year

2025

Operating status

Operating

Short description

Procyon Diagnostics is a 2025 UK spinout from Queen Mary University of London developing PancRISK, a patented urine-based ELISA plus machine learning assay for early-stage pancreatic cancer detection, targeting clinical laboratories and healthcare providers across Europe, North America, and the Middle East.

Ownership category

akta.pro rank

Product category

In-vitro Cancer Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Urinalysis & Routine Screening Diagnostics (HLAHAAAG)

akta.pro secondary industry

Pancreaticobiliary Disorders (HLAKAEAG)

Keywords

• Cancer diagnostics
• Early detection assays
• Biomarker panels
• In-vitro diagnostics
• Pancreatic cancer testing

Headquarters

HQ city

Skipton

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Test Sales: Procyon Diagnostics plans to generate revenue through the sale of diagnostic tests. The company aims to offer accurate and affordable non-invasive cancer detection tests with fast turnaround times. Revenue will be derived from test kit sales to healthcare providers and laboratories.

Go-to-market motion1 record

Distribution channels2 records

Core offering

Procyon Diagnostics is developing PancRISK, a non-invasive in-vitro diagnostic test that detects early-stage (Stage I-II) pancreatic cancer through a patented three-protein urinary biomarker panel analyzed via standard ELISA methodology and combined with a proprietary machine-learning-based risk-scoring algorithm. The test is being validated in the UroPanc clinical trial with planned commercial launch in Q4 2026, targeting hospitals, cancer centers, and clinical laboratories. PancRISK is positioned as an accurate, affordable, and rapid (approximately one-day turnaround) screening tool that can identify pancreatic cancer up to two years before clinical diagnosis.

Product overview

Procyon Diagnostics is a single-product company spun out from Queen Mary University of London, focused on early cancer detection. The company's sole product is PancRISK, a non-invasive urine-based test for pancreatic cancer detection. The product uses a patented panel of three protein biomarkers analyzed via ELISA and processed through a proprietary algorithm (PancRISK score) to classify patients as having increased or average risk of pancreatic cancer. The test is currently in clinical validation (UroPanc trial) and planned for commercial launch in Q4 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• PancRISK Non-invasive pancreatic cancer detection test using a patented three-protein urinary biomarker panel analyzed via standard ELISA methodology and processed through a proprietary risk-scoring algorithm enhanced with machine learning. Detects early-stage (Stage I-II) pancreatic cancer with approximately 90% accuracy, can identify cancer up to 2 years before clinical diagnosis, has a turnaround time of approximately one day, and runs on standard clinical laboratory instrumentation. Intended for sale to hospitals, cancer centers, and clinical laboratories for use with high-risk individuals (hereditary risk factors) and patients presenting with vague symptoms potentially associated with pancreatic cancer.

Quantifiable outcome

• Approximately 90% accuracy in detecting early-stage (Stage I-II) pancreatic cancer
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

One partnership is on record.

• Queen Mary University of LondoncoreStrategic or Co-development Partner · 22 October 2025Procyon Diagnostics is a spinout company from Queen Mary University of London. The company's technology, including the PancRISK test invented by Professor Tatjana Crnogorac-Jurcevic, originated from QMUL research and development at the Barts Cancer Institute. The company aims to commercialize clinical biomarker technology arising from QMUL research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oncimmune Holdings: Oncimmune is a UK-based diagnostics company with early cancer detection products (EarlyCDT) for lung and other cancers — directly comparable as a UK-headquartered early cancer detection diagnostics peer with similar commercial-stage IVD go-to-market.
• Bluestar Genomics: Bluestar Genomics was a US-based liquid biopsy company focused on non-invasive early detection of pancreatic cancer and other cancers using epigenomic biomarkers — directly comparable product approach (multi-analyte biomarker panel + ML) for the same pancreatic indication.
• Volition Diagnostics (VolitionRx): Volition develops Nu.Q blood-based epigenetic biomarker tests for cancer detection — same category of biomarker-driven IVD oncology diagnostics serving hospital/lab customers with CE-marked/marketed products.
• Immunovia: Immunovia is a Swedish diagnostics company developing the IMMray PanCan-d blood-based test for early detection of pancreatic cancer in high-risk individuals — same clinical indication and end-user cohort as Procyon's PancRISK, with both targeting symptomatic and hereditary-risk patients.

Emerging players

• AnchorDx: AnchorDx is an early-stage, Asia-based company developing methylation-based liquid biopsy assays for early cancer detection — comparable as an emerging-stage cancer detection diagnostics peer using advanced biomarker + AI analytics.
• Thrive Earlier Detection: Thrive was a blood-based multi-cancer early detection startup (acquired by Exact Sciences) developing a methylation-based screening test — comparable as an emerging-stage cancer detection peer that exited to a strategic acquirer, providing a relevant template for Procyon's exit path.

Broad incumbents

• Guardant Health: Guardant Health is a leading liquid biopsy company with oncology screening and monitoring products — broader oncology scope than Procyon but addresses the same hospital/lab customer base and competes in the cancer detection category.
• Exact Sciences: Exact Sciences markets Cologuard and acquired Thrive Earlier Detection — a large, established cancer screening diagnostics incumbent that competes with Procyon in the early detection category and represents a potential strategic acquirer.
• GRAIL: GRAIL is the dominant multi-cancer early detection (MCED) player with the Galleri test — broader product (50+ cancer signals vs single-cancer focus) and substantially larger scale, but directly relevant as the major competitive benchmark in early cancer detection.
• Freenome: Freenome is a well-funded multiomics blood-based early cancer detection company running large prospective trials — comparable as a private, larger-scale early cancer detection competitor with ML-driven biomarker analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Procyon Diagnostics